Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical company Eli Lilly has submitted an application with the European Medicines Agency for a review of Alimta, in combination with cisplatin, for the first-line treatment of advanced non-small cell lung cancer.
Subscribe to our email newsletter
The EMEA submission is based on a study which evaluated Alimta plus cisplatin versus Gemzar (gemcitabine HCl for injection) plus cisplatin. The study met its primary endpoint of non-inferiority relative to overall survival in a first-line non-small cell lung cancer (NSCLC) setting.
Richard Gaynor, vice president of cancer research and global oncology platform leader for Lilly said: “In this clinical study, Alimta plus cisplatin demonstrated similar efficacy to Gemzar plus cisplatin, a widely used regimen for first-line NSCLC, while providing a more favorable toxicity profile and greater convenience. We look forward to the outcome of the EMEA review.”